Nath Bio-Genes (India) Limited reported a 12% year-on-year increase in standalone net profit to ₹32.66 crore for the quarter ended June 30, 2026, driven by a 15% surge in revenue from operations to ₹322.84 crore. The company’s consolidated net profit rose 14% YoY to ₹32.26 crore, while consolidated revenue grew 16% to ₹328.40 crore. This performance underscores strong demand in its seed cultivation segment during the first quarter of FY27.

The Board of Directors approved the unaudited financial results at a meeting held on July 29, 2026, in compliance with Regulation 30, Regulation 33, and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee on July 28, 2026. Gautam N Associates, the statutory auditors, issued a limited review report on both standalone and consolidated financial statements, confirming they present true and fair views in accordance with Ind AS 34 and other recognized accounting practices.

Financial Performance

Standalone revenue from operations stood at ₹322.84 crore in Q1FY27, compared to ₹280.17 crore in the corresponding quarter of FY26. Total expenses were ₹28.88 crore, resulting in a profit from operations before other income and finance costs of ₹34.07 crore. Other income contributed ₹1.90 crore, while finance costs amounted to ₹3.79 crore. Exceptional items added ₹1.20 crore to the bottom line. After tax expenses of ₹0.72 crore, the standalone net profit reached ₹32.66 crore, up from ₹29.21 crore in Q1FY26. Earnings per share (basic and diluted) increased to ₹17.18 from ₹15.37 in the previous year.

On a consolidated basis, revenue from operations was ₹328.40 crore, compared to ₹283.70 crore in Q1FY26. Consolidated net profit was ₹32.26 crore, a significant improvement from ₹28.28 crore in the prior year period. Consolidated EPS rose to ₹16.98 from ₹14.88. The consolidation includes Nath Bio-Genes CA, Uzbekistan, where the company holds a 90% equity stake. A short provision of schemes amounting to ₹9.00 crore pertaining to Q4FY26 has been adjusted in the June 2025 results as per accounting standards.

Corporate Governance and AGM

The Board fixed September 24, 2026, as the date for the 33rd Annual General Meeting (AGM) of the company. The meeting will be held at 11:00 a.m. through video conference or other audio-visual means, in accordance with circulars issued by the Ministry of Corporate Affairs and SEBI. Details regarding book closure, record date, and participation procedures will be communicated separately. No investor complaints were received or remained pending during the quarter.

What the Numbers Show

The divergence between standalone and consolidated profitability highlights the impact of international operations. While standalone profit grew steadily, the consolidated figures reflect additional complexities from the Uzbekistan joint venture, including currency translation adjustments and specific local expenses. However, the consistent double-digit growth in both top-line revenue and bottom-line profit across both reporting bases indicates robust operational execution in the seed cultivation segment, which remains the company’s sole major product line.

Nath Bio-Genes (India) Limited disclosed that its promoters, along with relatives and persons acting in concert, collectively held 45.60% of the company's total equity shares as on March 31, 2026. The filing, submitted to BSE Limited and National Stock Exchange of India Ltd., details the shareholding structure for the financial year ended March 31, 2026. The total promoter holding stood at 86,64,902 equity shares at the end of the period.

During the financial year ended March 31, 2026, the promoter group made encumbrances on 11,94,000 equity shares directly or indirectly. The company confirmed that these encumbrances had already been disclosed previously. The disclosure was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The list of promoters and promoter group entities includes 17 distinct entities ranging from individual promoters to private limited companies and LLPs. The individual promoters named are Nandkishor Laxminarayan Kagliwal and Jeevanlata Nandkishor Kagliwal. The promoter group comprises entities such as Ferry Fax Farms Private Limited, Nath Biotechnologies Ltd, and Barkha Farms LLP.

The complete list of promoter entities is detailed below:

The filing was signed by Amol Gupta, Chief Financial Officer of Nath Bio-Genes (India) Limited, on behalf of the company. Satish Kagliwal submitted the declaration on behalf of the promoter and promoter group.